| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Julio Rosenstock | Q60996888 |
| Bernard Zinman | Q61337175 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 98-107 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Current Opinion in Endocrinology, Diabetes and Obesity | Q15756285 |
| P1476 | title | Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus | |
| P478 | volume | 14 |
| Q45334953 | A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes |
| Q51363561 | Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. |
| Q43275817 | Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia |
| Q35005772 | Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies |
| Q37794971 | Alogliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q85906676 | Bioassay-guided isolation of DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus |
| Q36188856 | Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study |
| Q37612696 | Defining the importance of daily glycemic control and implications for type 2 diabetes management |
| Q35988135 | Diabetes-related alterations in the enteric nervous system and its microenvironment |
| Q36124544 | Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis |
| Q41392226 | Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial |
| Q34273302 | Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes |
| Q46691051 | Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes |
| Q36715531 | In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies |
| Q33896508 | Incretin effect of Urena lobata leaves extract on structure and function of rats islet β-cells. |
| Q34237413 | Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes |
| Q40363153 | Liraglutide and DPP-4 inhibitors - side effects comparative clinical study |
| Q34046207 | Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation |
| Q51862698 | New gene targets for glucagon-like peptide-1 during embryonic development and in undifferentiated pluripotent cells. |
| Q37910902 | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. |
| Q33996721 | Pharmacophore Modeling and Molecular Docking Studies on Pinus roxburghii as a Target for Diabetes Mellitus. |
| Q37682555 | Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs |
| Q36945100 | Reflecting on type 2 diabetes prevention: more questions than answers! |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q35110343 | Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration |
| Q36945310 | SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete |
| Q38270204 | Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes |
| Q28259979 | Saxagliptin |
| Q38177173 | Sitagliptin: a review of its use in patients with type 2 diabetes mellitus |
| Q37703202 | Sitagliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q34575201 | Stimulating β-cell regeneration by combining a GPR119 agonist with a DPP-IV inhibitor |
| Q35855698 | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose |
| Q83380217 | The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells |
| Q37606032 | The usefulness of a Mediterranean-based diet in individuals with type 2 diabetes |
| Q37660219 | Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus |
| Q37082840 | Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes |
Search more.